Reduced syndecan-1 expression stimulates heparin-binding growth factor-mediated invasion in ovarian cancer cells in a urokinase-independent mechanism

Oncology Reports

Volumn 14, Issue 2, 2005, Pages 449-457

  Matsuzaki, Hidenori ^a   Kobayashi, Hiroshi ^b   Yagyu, Tatsuo ^a   Wakahara, Kiyoshi ^a   Kondo, Toshiharu ^c   Kurita, Noriyuki ^d   Sekino, Hideo ^d   Inagaki, Kiyokazu ^a   Suzuki, Mika ^b   Kanayama, Naohiro ^b   Terao, Toshihiko ^b  

^a NetForce Co Ltd   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Computer Technology Integration ^*  (Japan)

^d TOYOHASHI UNIVERSITY OF TECHNOLOGY   (Japan)

Author keywords

Adhesion; Antisense; Heparin binding growth factor; Invasion; Ovarian cancer; Syndecan 1

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; MEMBRANE PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEOGLYCAN; SDC1 PROTEIN, HUMAN; SOMATOMEDIN C; SYNDECAN; SYNDECAN 1; UROKINASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CELL MOTION; CELL PROLIFERATION; COMPARATIVE STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; NORTHERN BLOTTING; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEOGLYCANS; RNA, MESSENGER; SYNDECAN-1; SYNDECANS; TRANSFECTION; URINARY PLASMINOGEN ACTIVATOR;

EID: 24744446269     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.2.449     Document Type: Article

References (36)

1. Jackson RL, Busch SJ and Cardin AD: Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 71: 481-539, 1991.
2. Delehedde M, Deudon E, Billy B and Hondermarck H: Heparan sulfate proteoglycans play a dual role in regulating fibroblast growth factor-2 mitogenic activity in human breast cancer cells. Exp Cell Res 229: 398-406, 1996. (Pubitemid 27026930)
3. Delehedde M, Deudon E, Boilly B and Hondermarck H: Production of sulfated proteoglycans by human breast cancer cell lines: binding to fibroblast growth factor-2. J Cell Biochem 64: 605-617, 1997. (Pubitemid 27154514)
4. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J and Zako M: Functions of cell surface heparan sulfate proteoglycans. Ann Rev Biochem 68: 729-777, 1999. (Pubitemid 29449208)
5. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL and Lose EJ: Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Ann Rev Cell Biol 8: 365-393, 1992. (Pubitemid 23001002)
6. Inki P and Jalkanen M: The role of syndecan-1 in malignancies. Ann Med 28: 63-67, 1996. (Pubitemid 26056048)
7. Jayson G.C, Vives C, Paraskeva C, Schofield K, Coutts J, Fleetwood A and Gallagher JT: Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. Int J Cancer 82: 298-304, 1999. (Pubitemid 29293792)
8. Bayer-Garner IB and Smoller BR: The expression of syndecan-1 is preferentially reduced compared with that of E-cadherin in acantholytic squamous cell carcinoma. J Cutan Pathol 28: 83-89, 2001. (Pubitemid 32056615)
9. Fujiya M, Watari J, Ashida T, Honda M, Yanabe H, Fujiki T, Saiyoh Y and Kohgo Y: Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 92: 1074-1081, 2001. (Pubitemid 33041176)
10. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, Boguslawski KV and Haglund C: Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 95: 1-6, 2001.
11. Mali M, Andtfolk H, Miettinen HM and Jalkanen M: Suppression of tumor cell growth by syndecan-1 ectodomain. J Biol Chem 269: 27795-27798, 1994. (Pubitemid 24354496)
12. Inki P, Larjava H, Haapasalmi K, Miettinen HM, Grenman R and Jalkanen M: Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes. Eur J Cell Biol 63: 43-51, 1995. (Pubitemid 2039154)
13. Suzuki M, Kobayashi H, Tanaka Y, et al: Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin. Int J Cancer 104: 289-302, 2003. (Pubitemid 36249811)
14. Mali M, Jaakkola P, Arvilommi AM and Jalkanen M: Sequence of human syndecan indicates a novel gene family of integral membrane proteoglycans. J Biol Chem 265: 6884-6889, 1990.
15. Suzuki M, Kobayashi H, Tanaka Y, Hirashima Y and Terao T: Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins. Biochim Biophys Acta 1547: 26-36, 2001. (Pubitemid 32441559)
16. Kobayashi H, Suzuki M, Tanaka Y, Hirashima Y and Terao T: Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways. J Biol Chem 276: 2015-2022, 2001. (Pubitemid 32109681)
17. Kobayashi H, Suzuki M, Kanayama N, Nishida T, Takigawa M and Terao T: Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade. Eur J Biochem 269: 3945-3957, 2002. (Pubitemid 34994889)
18. Kobayashi H, Suzuki M, Tanaka Y, Kanayama N and Terao T: A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade. J Biol Chem 278: 7790-7799, 2003. (Pubitemid 36800512)
19. Suzuki M, Kobayashi H, Tanaka Y, et al: Bikunin target genes in ovarian cancer cells identified by microarray analysis. J Biol Chem 278: 14640-14646, 2003. (Pubitemid 36799786)
20. Kikuno K, Kita K, Nomura J, Hiwasa T, Yonemitsu H and Suzuki N: Search for genes responsible for UV susceptibility of human cells: involvement of syndecan-1 in UV resistance. Biochem Biophys Res Commun 253: 519-523, 1998. (Pubitemid 29026734)
21. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V and Reuning U: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78: 285-296, 1997. (Pubitemid 27289256)
22. Boudreau N and Bissell MJ: Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr Opin Cell Biol 10: 640-646, 1998. (Pubitemid 28477023)
23. Leppa S, Mali M, Miettinen HM and Jalkanen M: Syndecan expression regulates cell morphology and growth of mouse mammary epithelial tumor cells. Proc Natl Acad Sci USA 89: 932-936, 1992.
24. Day RM, Hao X, Ilyas M, Daszak P, Talbot IC and Forbes A: Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch 434: 121-125, 1999. (Pubitemid 29184989)
25. Liebersbach BF and Sanderson RD: Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 269: 20013-20019, 1994. (Pubitemid 24250921)
26. Ellerbroek SM, Stack MS: Membrane associated matrix metalloproteinases in metastasis. Bioessay 21: 940-949, 1999. (Pubitemid 29530603)
27. Westermarck J and Kahari V: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13: 781-792, 1999. (Pubitemid 29220691)
28. Park H, Kim Y, Lim Y, Han I and Oh E: Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 277: 29730-29736, 2002.
29. Dunn SE, Torres JV, Oh JS, Cykert DM and Barrett JC: Upregulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res 61: 1367-1374, 2001. (Pubitemid 34292558)
30. Dufourny B, Alblas J, van Teeffelen HA, et al: Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 272: 31163-31171, 1997. (Pubitemid 27527567)
31. Carey DJ: Syndecans: multifunctional cell-surface co-receptors. Biochem J 327: 1-16, 1997.
32. Stanley MJ, Stanley MW, Sanderson RD and Zera R: Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 112: 377-383, 1999. (Pubitemid 30214778)
33. Matsuda K, Maruyama H, Guo F, et al: Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 61: 5562-5569, 2001. (Pubitemid 32694943)
34. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M and Kohgo Y: Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 74: 482-491, 1997. (Pubitemid 27486504)
35. Nackaerts K, Verbeken E, Deneffe G, Vanderschueren B, Demedts M and David G: Heparan sulfate proteoglycan expression in human lung-cancer cells. Int J Cancer 74: 335-345, 1997. (Pubitemid 27321806)
36. Mikami S, Ohashi K, Usui Y, et al: Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res 92: 1062-1073, 2001. (Pubitemid 33041175)